Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents
| Autor: | Rashidkhan Pathan, Riccardo Utili, Zoe H. Dailiana, Kamal Hamed, Nisichenko Dmitriy, Vassiliki Syriopoulou |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Microbiology (medical) medicine.medical_specialty Adolescent Drug-Related Side Effects and Adverse Reactions medicine.drug_class daptomycin 030106 microbiology Antibiotics effectiveness Antimicrobial Reports medicine.disease_cause 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine children medicine Humans adolescents 030212 general & internal medicine Child Intensive care medicine Gram-Positive Bacterial Infections staphylococci business.industry Infant Newborn Infant Clindamycin biochemical phenomena metabolism and nutrition bacterial infections and mycoses Antimicrobial medicine.disease Anti-Bacterial Agents Treatment Outcome Infectious Diseases chemistry Staphylococcus aureus Child Preschool Bacteremia EU-CORE Pediatrics Perinatology and Child Health Linezolid Vancomycin Female Daptomycin business Gram-positive infections medicine.drug |
| Zdroj: | The Pediatric Infectious Disease Journal |
| ISSN: | 0891-3668 |
| Popis: | Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus (MRSA), are known to be common pathogens in children and adolescents in both healthcare and community-associated infections.1–3 Treatment of resistant pathogens including MRSA and vancomycin-resistant enterococci remains challenging even with standard antimicrobial protocols.4–6 Higher mortality has been reported because of MRSA infections than infections caused by methicillin-susceptible S. aureus.7,8 Several treatment options are available for the management of MRSA infections in adults; however, these options are limited for pediatric patients owing to a lack of sufficient safety and efficacy data.1 Clindamycin, vancomycin and linezolid are currently the only antibiotics approved by the US Food and Drug Administration for the management of MRSA infections in pediatric patients.1 Daptomycin is a cyclic lipopeptide that is active against a wide range of Gram-positive bacteria. Its mechanism of action involves calcium-dependent binding to the bacterial cell membrane, resulting in rapid depolarization of the membrane potential and bacterial cell death, without cell lysis and release of inflammatory mediators.9,10 Daptomycin is a concentration-dependent bactericidal agent indicated for the treatment of adult patients with complicated skin and soft-tissue infection (cSSTI), right-sided endocarditis caused by S. aureus, and bacteremia associated with cSSTI or right-sided endocarditis.11 Daptomycin is not approved for the treatment of pediatric patients,12 and limited data are currently available regarding its use in the treatment of Gram-positive infections in this population.1 A few case reports and retrospective studies have described that use of daptomycin is beneficial in treating Gram-positive infections in children.2,12 The European Cubicin Outcomes Registry and Experience (EU-CORESM) study was a retrospective, noninterventional registry developed to collect real-world data on the use of daptomycin in the treatment of patients with Gram-positive infections. This subgroup analysis evaluated the safety and effectiveness of daptomycin in children and adolescent patients from the EU-CORE study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|